Developer docs
API playgroundTry for free, no card

Search company profiles

StethoMe

Full company profile

uuid0002mc5

Namestring
StethoMe
Websiteurl
stethome.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

StethoMe is a Poznan, Poland-based medical device company founded in 2015 that has developed the StethoMe® digital stethoscope, a consumer-facing auscultation device designed for home-based monitoring of respiratory sounds, with current positioning focused on asthma management. The company operates within the digital auscultation market, which leverages AI-powered analysis to interpret lung and heart sounds — a category forecast to reach $1.85 billion by 2030 at 15.7% CAGR. The product targets individual asthma patients who lack tools for continuous symptom monitoring between clinical visits, with the Polish-language website messaging "Kontroluj astmę ze StethoMe®" (Control your asthma with StethoMe) framing the value proposition around patient self-management.

The business model is direct-to-consumer hardware sales through the company's own e-commerce storefront (stethome.com), with revenue generated primarily through device sales to individual patients in a single domestic market. The company has accumulated approximately $7.9 million in disclosed funding across six rounds from 2015 through 2020, with investor participation from SpeedUp Venture Capital Group, TDJ Pitango Ventures, Manta Ray Ventures, Movens Capital, RST Ventures For Earth, and Google for Startups. Five co-founders remain in leadership roles — Wojciech Radomski (CEO), Paweł Elbanowski (COO), Jędrzej Kocinski (CSO & Head of Regulatory Affairs), Marcin Szajek (CTO), and Honorata Hafke-Dys (VP Product) — providing an unusual concentration of engineering, clinical science, and regulatory expertise for a company of its size (11–50 employees). The presence of a dedicated Head of Regulatory Affairs signals ongoing work on medical device certification pathways that would enable expansion beyond the current DTC model.

Short descriptiontext

StethoMe is a Poland-based medical device company that sells a digital auscultation stethoscope enabling home-based lung sound monitoring, targeting individual asthma patients through a direct-to-consumer model in its domestic market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPoznan, Poland
HQ citystring
Poznan
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
digital stethoscope devices, remote respiratory monitoring, home asthma management, digital auscultation technology, AI lung sound analysis
Industry1 code
PRIMARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Remote Patient Monitoring Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Digital Health Device Sales
TypeHardware Sales
Description

StethoMe generates revenue through the sale of its digital stethoscope hardware device designed for home asthma monitoring. Based on the direct-to-consumer positioning and digital health market patterns, the company likely combines hardware sales with potential ongoing subscription services for data analysis and monitoring.

stethome.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

StethoMe develops and sells the StethoMe® digital stethoscope, a hardware device combined with software that enables home-based digital auscultation of heart and lung sounds. The product is primarily marketed for asthma control and respiratory symptom monitoring, allowing patients to capture and analyze respiratory sounds from home between clinical visits.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

StethoMe® is a single core product offering focused on digital auscultation for asthma management. The product enables users to monitor and control their asthma through digital stethoscope technology.

Product and service1 record
1StethoMe® Digital Stethoscope
CategoryRemote Patient Monitoring Devices
Description

A digital auscultation device (digital stethoscope) designed for home-based asthma control and respiratory symptom monitoring. It enables patients to capture lung sounds at home between clinical visits, with associated software/AI analysis supporting objective respiratory tracking and sharing of data with physicians. Target users are individual asthma patients and, indirectly, healthcare professionals using the captured data for remote auscultation.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StethoMe

Remote Patient Monitoring Devicesstethome.com

StethoMe is a Poland-based medical device company that sells a digital auscultation stethoscope enabling home-based lung sound monitoring, targeting individual asthma patients through a direct-to-consumer model in its domestic market.

What StethoMe does

StethoMe is a Poznan, Poland-based medical device company founded in 2015 that has developed the StethoMe® digital stethoscope, a consumer-facing auscultation device designed for home-based monitoring of respiratory sounds, with current positioning focused on asthma management. The company operates within the digital auscultation market, which leverages AI-powered analysis to interpret lung and heart sounds — a category forecast to reach $1.85 billion by 2030 at 15.7% CAGR. The product targets individual asthma patients who lack tools for continuous symptom monitoring between clinical visits, with the Polish-language website messaging "Kontroluj astmę ze StethoMe®" (Control your asthma with StethoMe) framing the value proposition around patient self-management.

The business model is direct-to-consumer hardware sales through the company's own e-commerce storefront (stethome.com), with revenue generated primarily through device sales to individual patients in a single domestic market. The company has accumulated approximately $7.9 million in disclosed funding across six rounds from 2015 through 2020, with investor participation from SpeedUp Venture Capital Group, TDJ Pitango Ventures, Manta Ray Ventures, Movens Capital, RST Ventures For Earth, and Google for Startups. Five co-founders remain in leadership roles — Wojciech Radomski (CEO), Paweł Elbanowski (COO), Jędrzej Kocinski (CSO & Head of Regulatory Affairs), Marcin Szajek (CTO), and Honorata Hafke-Dys (VP Product) — providing an unusual concentration of engineering, clinical science, and regulatory expertise for a company of its size (11–50 employees). The presence of a dedicated Head of Regulatory Affairs signals ongoing work on medical device certification pathways that would enable expansion beyond the current DTC model.

StethoMe firmographics

Firmographics
Name
StethoMe
Website
https://stethome.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
StethoMe is a Poland-based medical device company that sells a digital auscultation stethoscope enabling home-based lung sound monitoring, targeting individual asthma patients through a direct-to-consumer model in its domestic market.
Ownership category
akta.pro rank

StethoMe industry classification

Industry
Product category
Remote Patient Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital stethoscope devices
  • Remote respiratory monitoring
  • Home asthma management
  • Digital auscultation technology
  • AI lung sound analysis

Where StethoMe is headquartered

Location

Headquarters

HQ city
Poznan
HQ country
Poland
HQ region
Europe

Markets served

StethoMe business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Digital Health Device Sales: StethoMe generates revenue through the sale of its digital stethoscope hardware device designed for home asthma monitoring. Based on the direct-to-consumer positioning and digital health market patterns, the company likely combines hardware sales with potential ongoing subscription services for data analysis and monitoring.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

StethoMe product offering

Product offering

Core offering

StethoMe develops and sells the StethoMe® digital stethoscope, a hardware device combined with software that enables home-based digital auscultation of heart and lung sounds. The product is primarily marketed for asthma control and respiratory symptom monitoring, allowing patients to capture and analyze respiratory sounds from home between clinical visits.

Product overview

StethoMe® is a single core product offering focused on digital auscultation for asthma management. The product enables users to monitor and control their asthma through digital stethoscope technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • StethoMe® Digital Stethoscope A digital auscultation device (digital stethoscope) designed for home-based asthma control and respiratory symptom monitoring. It enables patients to capture lung sounds at home between clinical visits, with associated software/AI analysis supporting objective respiratory tracking and sharing of data with physicians. Target users are individual asthma patients and, indirectly, healthcare professionals using the captured data for remote auscultation.

Companies that use StethoMe

Customer profile

Segments1 record

Ideal customer profiles2 records

StethoMe technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

StethoMe partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

StethoMe competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

StethoMe social profiles

Digital presence

StethoMe financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StethoMe leadership team

Management profile

Number of profiles

Profiles5 records

StethoMe funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StethoMe M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StethoMe

What does StethoMe do?

StethoMe develops and sells the StethoMe® digital stethoscope, a hardware device combined with software that enables home-based digital auscultation of heart and lung sounds. The product is primarily marketed for asthma control and respiratory symptom monitoring, allowing patients to capture and analyze respiratory sounds from home between clinical visits.

Is StethoMe a public or private company?

StethoMe is a private company. It is classified as venture growth investor backed and is currently operating.

When was StethoMe founded?

StethoMe was founded in 2015. It employs 11 to 50 people.

Where is StethoMe based?

StethoMe is headquartered in Poznan, Poland, in the Europe region.

How does StethoMe make money?

One revenue line is on record: digital Health Device Sales.

Does StethoMe have an API?

No public API is recorded for StethoMe.

What industry is StethoMe in?

StethoMe's product category is Remote Patient Monitoring Devices. Its primary akta.pro industry code is HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech.euFrom smart stethoscopes to needle-free injections: European startups take centre stage at CESEuropean health startups are showcasing innovations at CES, including FlowBeams' needle-free injection, Dose's smart patch, and StethoMe's AI stethoscope. Vivoo unveiled a smart toilet for urine testing, with home availability planned for 2026.TechCrunchStethoMe’s smart stethoscope lets your kid’s doctor listen to their lungs from afarStethoMe, a startup competing at TechCrunch Disrupt, has developed a smart connected stethoscope enabling parents to perform lung examinations on children with asthma at home, sending AI-analyzed recordings to doctors with flags for wheezing, rhonci, or crackles.ITKeyMediaTech Movers’ Fund to Invest €13M in Early-Stage CEE StartupsMovens VC, a Warsaw-based fund, will invest €13M in early-stage CEE startups, with the Polish Development Fund as majority shareholder. Its first investment is StethoMe, a medtech company, and three more investments are planned. The fund focuses on fintech, martech, SaaS, and AI-driven solutions.www.money.plFPT zainaugurował projekt 'Technologie kontra COVID-19'FPT launched the 'Technologies Against COVID-19' project, showcasing startups that support the medical sector during the pandemic. The startups, including Telemedi.co, StethoMe, and Neuroforma, offer remote medical consultations, AI-based lung diagnostics, and home rehabilitation. The project aims to transform healthcare into an online era.PolskieRadio.plВ Варшаве вручены награды в рамках конкурса «Польские продукты будущего»In Warsaw, awards were given for the "Polish Products of the Future" competition, with Poznan-based StethoMe winning the main prize for its smart stethoscope. The company's co-founder said the prize will help promote the product abroad. The competition featured 96 projects across medicine, chemistry, electronics, and biotechnology.pb.plInnowacje made in Poland podbiją światPolish innovation leaders were awarded by PARP and NCBiR for the Polish Product of the Future competition. StethoMe won the main prize for a stethoscope detecting lung infections, while ML System received a special prize for photovoltaic glass reducing heating by 80 percent. The competition has now awarded 58 projects and 123 special prizes over 22 years.GloswielkopolskiInnowacyjny produkt przyszłości poznańskich naukowców doceniony! W konkursie "Polski Produkt Przyszłości" zdobył główną nagrodęPoznań-based researchers from StethoMe won the main prize in the "Polish Product of the Future" competition for their electronic stethoscope with a thermometer. The company received 100,000 PLN, and the device allows patients to perform home lung and heart auscultation via a mobile app.Emerging Europe10 start-ups from emerging Europe to watch in 2020Ten European start-ups are profiled, including Sharp3d, Mintos, Typing DNA, and others, with details on their technologies and funding. Sharp3d has raised €6M, Mintos €7M, and Typing DNA $1.3M, among others.The Medical FuturistA Digital Stethoscope For Your KidsStethoMe, a Poland-based company, offers an AI-powered home stethoscope for children that analyzes respiratory and heart sounds. The device has received CE marking and is awaiting FDA approval. The company is also developing algorithms for adult respiratory and heart sounds.MamStartupZ sukcesem zakończyliśmy pilotaż i przygotowujemy się do komercjalizacji. Podsumowanie roku StethoMeStethoMe, a lung and heart anomaly detection system, completed a successful pilot with Nationale-Nederlanden and Telemedico, achieving an NPS of 78 and 87% recommendation rate. The company plans commercialization in 2020 and is preparing new AI algorithms and a professional version.